Recursion Pharmaceuticals, Inc.
RXRX
$5.68
-$0.27-4.54%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.18% | -86.67% | 1.74% | -6.75% | 1.75% |
| Total Depreciation and Amortization | 49.26% | 79.92% | -19.74% | 21.57% | -2.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 28.27% | 66.25% | 61.00% | -8.43% | -19.83% |
| Change in Net Operating Assets | -196.76% | 126.86% | 125.97% | 71.84% | -223.43% |
| Cash from Operations | -14.32% | -94.90% | 27.97% | 19.63% | -38.10% |
| Capital Expenditure | -41.14% | 71.55% | -285.96% | 82.23% | -221.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -185.71% | -- | 100.00% | -- | -- |
| Cash from Investing | -102.64% | 6,138.05% | -9.09% | 37.14% | -167.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 2.57% | 8.13% | -8,696.15% | 0.00% | 96.25% |
| Issuance of Common Stock | 234.18% | -32.05% | -92.88% | 1,790.02% | -82.89% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 280.93% | -35.37% | -93.74% | 1,793.37% | -82.77% |
| Foreign Exchange rate Adjustments | 239.20% | -961.54% | 441.53% | 46.12% | -276.61% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -156.14% | 456.32% | -126.57% | 285.36% | -2,358.77% |